https://doi.org/10.4081/monaldi.2023.2755
Comparison of immediate withdrawal and stepwise reduction in duration of non-invasive ventilation in chronic obstructive pulmonary disease patients presenting with acute hypercapnic respiratory failure
Accepted: September 27, 2023
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
There is no universally acceptable protocol for the withdrawal of non-invasive ventilation (NIV) in chronic obstructive pulmonary disease (COPD) patients presenting with acute hypercapnic respiratory failure (AHcRF). This study was carried out to evaluate immediate against stepwise reduction in NIV. Sixty COPD patients with AHcRF who were managed with NIV were randomized into two groups: immediate NIV withdrawal (group A) and stepwise reduction of NIV duration (group B). The rate of successful NIV withdrawal, time to recurrence of hypercapnic respiratory failure, total duration of NIV use, and hospital length of stay (LOS) were compared among the two groups. NIV was successfully withdrawn in 51/60 (85 %) patients. NIV was successfully withdrawn in 24/30 (80%) patients in group A and 27/30 (90%) patients in group B (p=0.472). The total duration of NIV use was significantly lower in group A (38.97±17 hours) as compared to group B (64.3±7.74 hours) (p<0.0001). LOS was significantly lower in group A (5.8±1.6 days) as compared to group B (7.7±0.61 days) (p<0.0001). To conclude, immediate withdrawal of the NIV after recovery from respiratory failure among patients with exacerbation of COPD is feasible and does not increase the risk of weaning failure.
Ethics Approval
This study was approved by the Institutional Ethics Committee of Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi (Number - IEC/VMMC/SJH/Thesis 2021-05/CC-21 dated 11/6/2021).How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Brandon Iturbe Esquivel, José Meneses Calderón, Luis Edgar Concepción Carrillo, Hugo Mendieta Zeron, Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series , Monaldi Archives for Chest Disease: Vol. 93 No. 1 (2023)
- Vasileios Karamouzos, Fotini Fligou, Charalambos Gogos, Dimitrios Velissaris, High flow nasal cannula oxygen therapy in adults with COVID-19 respiratory failure. A case report , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
- Marcos Martinelli, Eduardo V. Ponte, Daniel Antunes S. Pereira, Giulio Checchinato , Bruna Eduarda Gandra, Bruno Maciel, Alcides Rocha, Relationship between symptoms and results on spirometry in adults seen in non-tertiary public health facilities presenting with preserved ratio impaired spirometry , Monaldi Archives for Chest Disease: Early Access
- Yuvarajan Sivagnaname, Praveen Radhakrishnan, Antonius Maria Selvam, Malignant bronchial ulcer with coexistent pulmonary tuberculosis , Monaldi Archives for Chest Disease: Vol. 89 No. 3 (2019)
- Pietro Impellizzeri, Santi Nolasco, Raffaele Campisi, Antonino Cipolla, Alba Borgese, Stefano Alia, Nunzio Crimi, Claudia Crimi, Acute and long-term management of severe bronchiectasis with high flow nasal therapy: a case report , Monaldi Archives for Chest Disease: Vol. 93 No. 2 (2023)
- Kamal Kant Sahu, Ajay Kumar Mishra, Kevin Martin, Iryna Chastain, COVID-19 and restrictive lung disease: A deadly combo to trip off the fine balance , Monaldi Archives for Chest Disease: Vol. 90 No. 2 (2020)
You may also start an advanced similarity search for this article.
